Related Experiment Video
Updated: Feb 1, 2026

Isolation of Murine Coronary Vascular Smooth Muscle Cells
Published on: May 30, 2016
Losartan inhibits EGFR transactivation in vascular smooth muscle cells
Mustafa Kırça1, Akın Yeşilkaya1
1Department of Biochemistry, School of Medicine, Akdeniz University, Antalya, Turkey
Background/Aim:
Angiotensin II (Ang II)-induced molecular signaling pathways play a significant role in the progression of cardiovascular diseases, including hypertension and atherosclerosis. In addition to the well-known effects of Ang II, it may activate epidermal growth factor receptor (EGFR) in a process known as transactivation, which contributes to vascular pathologies. The aim of this study was to determine whether losartan could reduce EGFR transactivation induced by Ang II. Additionally, we evaluated the roles of heparin-binding epidermal-like growth factor (HB-EGF) and matrix metalloproteinases (MMPs) in Ang II-induced EGFR transactivation.
Materials And Methods:
Vascular smooth muscle cells were isolated from a rat aorta and grown in primary culture. Ang II-induced EGFR phosphorylation (tyrosine 1068) and ERK1/2 MAPK phosphorylation (threonine 202 and tyrosine 204) were evaluated by western blotting.
Results:
Ang II induced EGFR phosphorylation through the Ang II type I receptor (P < 0.05). The transactivation process was inhibited by losartan and mediated by HB-EGF and MMPs. Ang II transactivates EGFR in an AT1R-dependent manner.
Conclusion:
The results of this study show that losartan, a widely used antihypertensive agent, can suppress EGFR phosphorylation (Y1068) upon Ang II stimulation in vascular smooth muscle cells. EGFR inhibition is a candidate therapy for combating cardiovascular diseases such as hypertension and atherosclerosis.
Insights
Losartan, an antihypertensive drug, inhibits Angiotensin II-induced EGFR transactivation in vascular cells. This finding suggests EGFR inhibition as a potential therapy for cardiovascular diseases like hypertension.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Pharmacology
Background:
- Angiotensin II (Ang II) signaling contributes to cardiovascular diseases.
- Ang II may activate epidermal growth factor receptor (EGFR) via transactivation, promoting vascular pathologies.
- The roles of HB-EGF and MMPs in Ang II-induced EGFR transactivation require further investigation.
Purpose of the Study:
- To determine if losartan reduces Ang II-induced EGFR transactivation.
- To investigate the involvement of heparin-binding epidermal-like growth factor (HB-EGF) and matrix metalloproteinases (MMPs) in this process.
Main Methods:
- Vascular smooth muscle cells were cultured from rat aortas.
- Angiotensin II-induced EGFR and ERK1/2 MAPK phosphorylation were assessed using western blotting.
Main Results:
- Ang II induced EGFR phosphorylation via the Ang II type I receptor (AT1R).
- Losartan effectively inhibited Ang II-induced EGFR transactivation.
- This process was mediated by HB-EGF and MMPs, confirming an AT1R-dependent mechanism.
Conclusions:
- Losartan suppresses EGFR phosphorylation stimulated by Ang II in vascular smooth muscle cells.
- EGFR inhibition presents a potential therapeutic strategy for hypertension and atherosclerosis.
Related Concept Videos
Functions of Smooth Muscles
Function of visceral smooth muscles
Visceral smooth muscle is found in the walls of all hollow organs, except the heart, and is a key player in the involuntary movements that drive the functioning of these internal organs. This tissue is arranged in...
Smooth Muscle Contraction
The onset of contraction is triggered by an increase in calcium ions within the sarcoplasm, similar to the process in striated muscle. However, smooth muscles have a relatively smaller reservoir of the sarcoplasmic...
Structure and Organization of Smooth Muscles
Structure of smooth muscle cell
Smooth muscle cells are spindle-shaped with tapering ends and a...
Feedback Inhibition
Seedless Vascular Plants
Smooth Endoplasmic Reticulum
The ER provides optimal conditions for synthesizing steroid hormones and lipids, such as phospholipids and triglycerides. Traditionally, lipid metabolism was considered to be a smooth ER function. However, there is no direct evidence to prove that rough ER is completely excluded from lipid...

